The discovery of the molecular classification of breast cancer into 4 distinct subtypes, Luminal A, Luminal B, HER2-enriched, and basal-like (triple-negative), is an early structure with interpatient heterogeneity. This evidence concerns the gene ERBB2 and breast carcinoma.